| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 24th September 2020 | Louis Manzo | 8,299 | Exercise of derivative | $3.70 | $30,706.30 |
| 27th July 2020 | Linda Marban | 41,497 | Exercise of derivative | $3.70 | $153,538.90 |
| 27th July 2020 | Linda Marban | 15,652 | Payment by withholding | $9.81 | $153,546.12 |
| 17th December 2019 | Louis Manzo | 20,391 | Grant/award etc. | $0.00 | |
| 17th December 2019 | David B Musket | 20,391 | Grant/award etc. | $0.00 | |
| 17th December 2019 | Frank Litvack | 20,391 | Grant/award etc. | $0.00 |
Capricor Therapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 3/10.
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps.
Ticker: CAPR
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1133869
Employees: 22
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
News
Behind real estate’s surprise 2020 boom and what comes next
24th October 2020
US judge will not reverse decision on WeChat app store ban
23rd October 2020